PXD042499 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Ezrin inhibition overcomes acquired resistance to vemurafenib in BRAFV600E-mutated colon cancer and melanoma cells in vitro |
Description | In spite of the advancements in targeted therapy for BRAFV600E-mutated metastatic colorectal cancer (mCRC), the development of resistance to BRAFV600E inhibition limits the response rate and durability of the treatment. Better understanding of the resistance mechanisms to BRAF inhibitors will facilitate the design of novel pharmacological strategies for BRAF-mutated mCRC. The aim of this study was to identify novel protein candidates involved in acquired resistance to BRAFV600E inhibitor vemurafenib in BRAFV600E-mutated colon cancer cells using an integrated proteomics approach. Our study suggests a role of ezrin in acquired resistance to vemurafenib in colon cancer and melanoma cells carrying BRAFV600E mutation and supports further pre-clinical and clinical studies to explore the benefits of combined BRAF inhibitors and actin-targeting drugs as a potential therapeutic approach for BRAFV600E-mutated cancers. |
HostingRepository | PRIDE |
AnnounceDate | 2023-11-14 |
AnnouncementXML | Submission_2023-11-14_09:04:55.141.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Antje Dittmann |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | monohydroxylated residue; iodoacetamide derivatized residue |
Instrument | Q Exactive HF |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2023-05-25 08:46:22 | ID requested | |
1 | 2023-08-29 02:38:24 | announced | |
⏵ 2 | 2023-11-14 09:05:02 | announced | 2023-11-14: Updated project metadata. |
Publication List
Car I, Dittmann A, Vasieva O, Bo, č, kor L, Grb, č, i, ć P, Pite, š, a N, Klobu, č, ar M, Kraljevi, ć, Paveli, ć S, Sedi, ć M, Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro. Int J Mol Sci, 24(16):(2023) [pubmed] |
Keyword List
ProteomeXchange project tag: EPIC-XS |
submitter keyword: ezrin,BRAFV600E, actin cytoskeleton, NSC305787, colon cancer, ezrin inhibitor, melanoma, BRAF inhibitor, vemurafenib |
Contact List
Mirela Sedic |
contact affiliation | Centre for Applied Bioanthropology, Institute for Anthropological Research, Zagreb, Croatia |
contact email | mirela.sedic@inantro.hr |
lab head | |
Antje Dittmann |
contact affiliation | ETH |
contact email | antje.dittmann@gmail.com |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/08/PXD042499 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD042499
- Label: PRIDE project
- Name: Ezrin inhibition overcomes acquired resistance to vemurafenib in BRAFV600E-mutated colon cancer and melanoma cells in vitro